Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05314517 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis
A Phase 2 study, sponsored by Kinevant Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
NCT05314517 is a Phase 2 study that was terminated before completion, run by Kinevant Sciences. The registered enrollment target is 107 participants.
The verdict
NCT05314517, a Phase 2 study, was terminated before completion, sponsored by Kinevant Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled study with an open-label extension (OLE).
Interventions
- DRUG Placebo
- DRUG Namilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2025-04-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05314517
The ClinicalTrials.gov registry entry for NCT05314517 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kinevant Sciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05314517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05314517 about?
NCT05314517 is a clinical study titled "A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis". This is a randomized, double-blind, placebo-controlled study with an open-label extension (OLE).
What is the current status of trial NCT05314517?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2022-08-31. Estimated completion is 2025-04-09.
What interventions are being tested in trial NCT05314517?
The interventions under investigation include: Placebo (DRUG), Namilumab (DRUG).
Who is sponsoring clinical trial NCT05314517?
This trial is sponsored by Kinevant Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.